Alumis (NASDAQ:ALMS) & Fate Therapeutics (NASDAQ:FATE) Critical Comparison

Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Alumis (NASDAQ:ALMS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Insider & Institutional Ownership

97.5% of Fate Therapeutics shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 33.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Fate Therapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Alumis has a beta of -0.28, indicating that its stock price is 128% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Fate Therapeutics and Alumis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics 1 1 4 0 2.50
Alumis 1 1 11 1 2.86

Fate Therapeutics currently has a consensus target price of $5.80, suggesting a potential upside of 411.01%. Alumis has a consensus target price of $31.27, suggesting a potential upside of 519.88%. Given Alumis’ stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Fate Therapeutics.

Profitability

This table compares Fate Therapeutics and Alumis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fate Therapeutics -1,941.09% -73.92% -45.16%
Alumis -5,844.54% -89.77% -71.50%

Valuation and Earnings

This table compares Fate Therapeutics and Alumis”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fate Therapeutics $6.65 million 20.75 -$136.32 million ($1.03) -1.10
Alumis $7.40 million 88.27 -$243.32 million ($3.53) -1.43

Fate Therapeutics has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Fate Therapeutics beats Alumis on 8 of the 15 factors compared between the two stocks.

About Fate Therapeutics

(Get Free Report)

Fate Therapeutics is a clinical-stage biotechnology company based in San Diego, California. It develops cellular immunotherapies using induced pluripotent stem cells (iPSCs), which can be engineered and used to produce populations of therapeutic cells. The company’s research focuses on off-the-shelf cell therapies, including natural killer (NK) cell and T-cell programs designed to target cancer. Its approach aims to create standardized therapies that do not require cells to be collected from each individual patient.

About Alumis

(Get Free Report)

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.